665 related articles for article (PubMed ID: 15853577)
1. Ropinirole therapy for Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA
Expert Rev Neurother; 2004 Jul; 4(4):581-8. PubMed ID: 15853577
[TBL] [Abstract][Full Text] [Related]
2. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
3. Ropinirole in the symptomatic treatment of Parkinson's disease.
Brooks DJ; Torjanski N; Burn DJ
J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
[TBL] [Abstract][Full Text] [Related]
4. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
[TBL] [Abstract][Full Text] [Related]
5. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
[TBL] [Abstract][Full Text] [Related]
6. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
Pahwa R; Stacy MA; Factor SA; Lyons KE; Stocchi F; Hersh BP; Elmer LW; Truong DD; Earl NL;
Neurology; 2007 Apr; 68(14):1108-15. PubMed ID: 17404192
[TBL] [Abstract][Full Text] [Related]
7. Ropinirole: new preparation. Wait for more convincing data.
Prescrire Int; 1998 Apr; 7(34):36-8. PubMed ID: 10183378
[TBL] [Abstract][Full Text] [Related]
8. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
Buchwald B; Angersbach D; Jost WH
Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
[TBL] [Abstract][Full Text] [Related]
9. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
10. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
11. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies.
Onofrj M; Bonanni L; De Angelis MV; Anzellotti F; Ciccocioppo F; Thomas A
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S85-92. PubMed ID: 20123565
[TBL] [Abstract][Full Text] [Related]
12. Ropinirole: a review of its use in the management of Parkinson's disease.
Matheson AJ; Spencer CM
Drugs; 2000 Jul; 60(1):115-37. PubMed ID: 10929932
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
Tompson D; Oliver-Willwong R
Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
[TBL] [Abstract][Full Text] [Related]
14. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.
Mizuno Y; Abe T; Hasegawa K; Kuno S; Kondo T; Yamamoto M; Nakashima M; Kanazawa I;
Mov Disord; 2007 Oct; 22(13):1860-5. PubMed ID: 17618525
[TBL] [Abstract][Full Text] [Related]
15. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE; Abdalla M;
Mov Disord; 2006 Nov; 21(11):1844-50. PubMed ID: 16958094
[TBL] [Abstract][Full Text] [Related]
16. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
[TBL] [Abstract][Full Text] [Related]
17. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease.
Lyons KE; Pahwa R
Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728
[TBL] [Abstract][Full Text] [Related]
18. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
Brooks DJ; Abbott RJ; Lees AJ; Martignoni E; Philcox DV; Rascol O; Roos RA; Sagar HJ
Clin Neuropharmacol; 1998; 21(2):101-7. PubMed ID: 9579296
[TBL] [Abstract][Full Text] [Related]
19. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
20. Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease.
Barone P; Lamb J; Ellis A; Clarke Z
Mov Disord; 2007 Mar; 22(4):483-9. PubMed ID: 17115380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
